Biotechnology
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Ho...
2025-12-26 12:55
1100
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
* TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. * The TABOSUN® and TYVYT® c...
2025-12-25 16:45
698
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
* Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). * The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in...
2025-12-25 10:05
582
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&...
2025-12-24 22:00
669
Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth
CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the expansion of its integrated discovery and development framework to support early clinical development an...
2025-12-24 09:20
1099
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.
SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) onDecember 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug...
2025-12-24 07:37
1088
Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug developm...
2025-12-23 20:00
2103
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion protein inCell Reports Medicine. The peer-review...
2025-12-23 13:03
2180
Origin Agritech Holds Annual R&D and Operations Management Conference, Establishes 2026 Strategic Priorities
BEIJING, Dec. 22, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, announced the results of its Annual Research & Development and Operations Management Conference held at the Company'sBeijing headquarters from...
2025-12-22 21:36
2276
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therap...
2025-12-22 21:00
2828
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy
Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 /PRNewswire/ -- Guardant Health Japan Corp. today announced that the...
2025-12-22 16:00
2037
The 8th Hainan International Health Industry Expo opens in Sanya
HAIKOU, China, Dec. 22, 2025 /PRNewswire/ -- A report from Hainan International Media Center: On December 20, 2025, the 8th Hainan International Health Industry Expo opened in Sanya. Coinciding with the crucial juncture of the Hainan Free Trade Port's island-wide special customs operations, this...
2025-12-22 11:44
1553
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: * TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase ...
2025-12-22 05:40
2022
T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblas...
2025-12-21 20:20
2249
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
SUZHOU, China, Dec. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...
2025-12-20 12:54
4951
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards
SINGAPORE, Dec. 20, 2025 /PRNewswire/ -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held inSingapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts...
2025-12-20 11:14
4770
Pictor's Test Poised to Transform Hepatitis B Immunity Testing Amid CDC Guidance Shifts
CARLSBAD, Calif., Dec. 19, 2025 /PRNewswire/ -- With the CDC's Advisory
Committee on Immunization Practices (ACIP) recommending post-vaccination
antibody testing for hepatitis B, laboratories are facing new demands to assess
immunity more effectively. Pictor
2025-12-19 22:17
2797
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure. Climate Change Leadership Being recogn...
2025-12-19 17:30
3590
NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation ("CDE")of the National Medical Products Administration ("NM...
2025-12-19 09:46
3496
MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan
- South Korean biotech company secures US$8 million in upfront payment for the joint commercialization of the stem cell therapy CARTISTEM® targeting the Japanese knee osteoarthritis market. SEOUL, South Korea, Dec. 19, 2025 /PRNewswire/ -- MEDIPOST Co., Ltd. (KOSDAQ 078160), a fully integrated c...
2025-12-19 08:39
3182
Week's Top Stories
Most Reposted
One Universal Production Group (OUP) Officially Opens, Reinforcing Its Position as Asia's Leading IP Ecosystem and Tourism Company
[Picked up by 315 media titles]
2025-12-20 09:36
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 275 media titles]
2025-12-26 12:55The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup
[Picked up by 270 media titles]
2025-12-21 12:42
Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
